Table 1.
Mean±s.d. pharmacokinetic parameters for ziprasidone on days 5 and 13 during placebo and ketoconazole administration.
| Group 1 | Group 2 | ||||
|---|---|---|---|---|---|
| Day 5 Ziprasidone + ketoconazole (n = 6) | Day 13 Ziprasidone + placebo (n = 6) | Day 5 Ziprasidone + placebo (n = 7) | Day 13 Ziprasidone + ketoconazole (n = 7) | Pd (S, P effects) | |
| AUC(0,∞)a (ng ml−1 h) | 1107 ± 232 | 917 ± 165 | 882 ± 335 | 1299 ± 351 | 0.66, 0.23 |
| Cmaxa (ng ml−1) | 117 ± 36 | 101 ± 28 | 79 ± 31 | 121 ± 57 | 0.57, 0.19 |
| tmaxb (h) | 8.3 ± 2.9 | 7.0 ± 2.8 | 10.0 ± 2.6 | 10.0 ± 2.6 | 0.49, 0.55 |
| λzb (h−1) | 0.198 ± 0.067 | 0.177 ± 0.05 | 0.151 ± 0.029 | 0.169 ± 0.051 | 0.28, 0.88 |
| t½,zc (h) | 3.5 | 3.9 | 4.6 | 4.1 | – |
a
Geometric means and s.d.
b
Arithmetic means and s.d.
c
Calculated as ln 2/mean λz.
d
Significance for sequence (S) and period (P) effects, in that order.